about
How to calculate the dose of chemotherapyCYP3A4 and CYP3A5 genotyping by PyrosequencingGenome-wide discovery of drug-dependent human liver regulatory elementsPotentially increasing the metabolic stability of drug candidates via computational site of metabolism prediction by CYP2C9: The utility of incorporating protein flexibility via an ensemble of structuresPharmacologic considerations for therapeutic success with antiretroviral agents.Polymorphic cytochrome P450 2D6: humanized mouse model and endogenous substrates.Strategies to overcome simultaneous P-glycoprotein mediated efflux and CYP3A4 mediated metabolism of drugs.Combination lipid-lowering therapy with statins: safety issues in the postcerivastatin era.Hepatic cytochrome P450 degradation: mechanistic diversity of the cellular sanitation brigade.Intrinsic sexually dimorphic expression of the principal human CYP3A4 correlated with suboptimal activation of GH/glucocorticoid-dependent transcriptional pathways in men.Cytochromes P450 and MDR1 mRNA expression along the human gastrointestinal tract.Arsenic decreases RXRα-dependent transcription of CYP3A and suppresses immune regulators in hepatocytes.Modulation of oral drug bioavailability: from preclinical mechanism to therapeutic application.Nuclear receptors and the regulation of drug-metabolizing enzymes and drug transporters: implications for interindividual variability in response to drugs.Chicken cytochrome P450 1A5 is the key enzyme for metabolizing T-2 toxin to 3'OH-T-2Identification of polymorphisms in the 3'-untranslated region of the human pregnane X receptor (PXR) gene associated with variability in cytochrome P450 3A (CYP3A) metabolism.The generation, detection, and effects of reactive drug metabolites.Toxicogenetic profile and cancer risk in Lebanese.Treatment of gastroesophageal reflux disease: two new oral formulations dexlansoprazole MR and esomezol (esomeprazole strontium).Cytochrome P4503A (CYP3A) metabolism: prediction of in vivo activity in humans.Effect of erythropoietin on hepatic cytochrome P450 expression and function in an adenine-fed rat model of chronic kidney disease.Pharmacokinetic characteristics of ritonavir, zidovudine, lamivudine, and stavudine in children with human immunodeficiency virus infection.In vitro and in vivo studies to characterize the clearance mechanism and potential cytochrome P450 interactions of anidulafungin.Indinavir concentrations and antiviral effect.Identification of the human P450 enzymes involved in the in vitro metabolism of the synthetic steroidal hormones Org 4060 and Org 30659.Cytochrome P450 expression in human hepatocytes and hepatoma cell lines: molecular mechanisms that determine lower expression in cultured cells.Identification of the human cytochrome P450s responsible for the in vitro metabolism of a leukotriene B4 receptor antagonist, CP-195,543.Intraindividual variability in male hepatic CYP3A4 activity assessed by alfentanil and midazolam clearance.Effects of salidroside on rat CYP enzymes by a cocktail of probe drugs.Effects of smoking and body mass index on the exposure of fentanyl in patients with cancer.
P2860
Q24642872-3CE6062A-78AD-4C95-9C48-5BFECF539581Q24810187-37EB980F-D07C-4883-B968-C543E750032CQ28543477-FEB0FC05-D775-42F8-A601-B12A62A9686FQ30404209-B8DCB6F0-4099-4E6C-8FF9-B9158A259BCBQ33735400-92EE066D-749F-4C9F-9CDA-B79355D0F1CCQ34331552-EA3BB2F1-2334-41CC-9166-AF8086047504Q34448305-17F0A20C-FD59-47B6-91DD-1FD2F13B18E5Q35194386-56676C6D-E32C-48F1-9609-AF16042BC4E6Q35213373-6A7BFE3F-B7D5-4764-9775-B4AA059CA9F0Q35590828-A63BE0AB-AF3D-4597-8604-9C9A5FE0F9E0Q35827133-46268C3A-3EED-4215-9EDF-C37B082D86E9Q35939136-8EB86A11-6B78-43F7-B778-4F8715437F65Q36271954-9AC8C9E9-9770-423B-843C-3FB7637A782BQ36795136-22020DFA-A636-4DDB-87AA-D7991DDC3842Q37007063-3517EF30-9D5C-49DF-9EF9-E0EB2EF30F25Q37207247-DAF65C2A-79F4-4F2F-98A1-D7B898BB3639Q38054629-8488775E-F606-4DF6-A671-034C3A2A77CDQ38195853-07CD184D-35A7-4D13-9100-C61F7764B7D6Q38205882-50B6E772-CAAE-44EF-BB21-07A39DA8364AQ41456111-1B8286CA-4215-4F11-A72C-67BC82C07DACQ42552831-D96BE699-5573-4B32-99D1-31BDDCC5EA75Q42625394-D08F6429-1BD9-41A0-A556-A1544F278085Q43169846-D0AC5953-5AAA-476F-9747-7D50D99FDAB8Q43506115-C4C4B3A9-9C4B-4794-BFBC-89F8EB326434Q43900661-81CA49D3-7848-4959-80A2-21D6C9295332Q44087884-A105C73E-BF06-4A59-B70C-139A91C30AE8Q44741187-A9187ABE-B849-47CA-AD91-B2153CCA73E3Q51452446-25FF8E84-C89F-446E-BF6F-D71238423639Q55264312-E7DE44B5-CE21-4BB8-9469-695E5B865FF7Q55382249-EF6CA584-4CE6-4AEE-8ADD-D66343B19906
P2860
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
1996年论文
@zh
1996年论文
@zh-cn
name
The human drug metabolizing cytochromes P450.
@en
type
label
The human drug metabolizing cytochromes P450.
@en
prefLabel
The human drug metabolizing cytochromes P450.
@en
P2093
P2860
P356
P1476
The human drug metabolizing cytochromes P450.
@en
P2093
M VandenBranden
S A Wrighton
P2860
P2888
P304
P356
10.1007/BF02353474
P577
1996-10-01T00:00:00Z